Functional MRI for anticancer therapy assessment

Area of Science:

• Oncology
• Medical Imaging
• Pharmacology

Background:

• Cancer therapy is shifting towards targeted treatments, moving away from traditional cytotoxic drugs.
• Newer cancer therapies are often cytostatic, making tumor shrinkage an inadequate measure of efficacy.
• There's a critical need for surrogate endpoints to accelerate the evaluation of drug combinations in clinical trials.

Purpose of the Study:

• To review the emerging role of functional magnetic resonance imaging (fMRI) in cancer drug development.
• To explore fMRI's potential for pharmacodynamic evaluation of novel and existing cancer therapeutics.
• To discuss the integration of fMRI into clinical trial protocols.

Main Methods:

• Focus on dynamic contrast-enhanced MRI (DCE-MRI) as a key functional MRI technique.
• Review of DCE-MRI applications in evaluating anti-angiogenic and anti-vascular cancer agents.
• Discussion of the prerequisites for implementing functional MRI in clinical settings.

Main Results:

• Functional MRI, particularly DCE-MRI, shows promise as a surrogate endpoint for cancer drug efficacy.
• DCE-MRI is actively used in human trials to assess the impact of anti-angiogenic and anti-vascular therapies.
• The review highlights the technical and clinical considerations for adopting fMRI in cancer drug evaluation.

Conclusions:

• Functional MRI techniques are crucial for evaluating novel cancer therapeutics, especially cytostatic agents.
• DCE-MRI can serve as a valuable pharmacodynamic tool, potentially accelerating drug development timelines.
• Standardizing functional MRI protocols is essential for its widespread adoption in clinical cancer research.